Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.
ADI, alongside Newcastle University and the London School of Economics, is submitting an application to the WHO Expert Committee on the inclusion of anti-dementia medication and needs to hear from clinicians everywhere.
The project, launching 1 September, will aim to raise funds for ADI through the sale of a collection of photographs in the form of NFTs.
DY Suharya, ADI Regional director for Asia Pacific, will lead on a Values 20 (V20) work stream in preparation for the G20 summit, taking place on 15-16 November 2022.
If you are living with dementia, a carer, clinician, formal (paid) health or long-term care practitioner, we need to hear about your experience of post-diagnosis for the World Alzheimer Report 2022.
ADI is pleased to announce the formalisation of a long-standing collaboration with World Wide-FINGERS (WW-FINGERS) by joining in partnership to reduce the risk of dementia worldwide.